145 related articles for article (PubMed ID: 35347000)
1. Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies.
Zander T; Xue J; Markson G; Dahm F; Renner C
Anticancer Res; 2022 Apr; 42(4):1821-1832. PubMed ID: 35347000
[TBL] [Abstract][Full Text] [Related]
2. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
5. Satraplatin: an orally available platinum analog for the treatment of cancer.
Choy H
Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
[TBL] [Abstract][Full Text] [Related]
6. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
7. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
8. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
9. An update on satraplatin: the first orally available platinum anticancer drug.
Kelland LR
Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pharmacokinetic evaluation of satraplatin.
Doshi G; Sonpavde G; Sternberg CN
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):103-11. PubMed ID: 22098065
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
12. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ
Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
[TBL] [Abstract][Full Text] [Related]
13. Rapid biotransformation of satraplatin by human red blood cells in vitro.
Carr JL; Tingle MD; McKeage MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):9-15. PubMed ID: 12111106
[TBL] [Abstract][Full Text] [Related]
14. Satraplatin for the therapy of castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Future Oncol; 2009 Sep; 5(7):931-40. PubMed ID: 19792961
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
16. Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
He G; Xie X; Siddik ZH
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1129-1140. PubMed ID: 32468080
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
18. Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.
Kalimutho M; Minutolo A; Grelli S; Federici G; Bernardini S
Acta Pharmacol Sin; 2011 Nov; 32(11):1387-96. PubMed ID: 21927014
[TBL] [Abstract][Full Text] [Related]
19. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione.
Kostrhunova H; Kasparkova J; Gibson D; Brabec V
Mol Pharm; 2010 Dec; 7(6):2093-102. PubMed ID: 20936822
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
